Revvity, Inc., a key player in life sciences and diagnostics, witnessed a rebound in its stock price on Tuesday. This uptick occurred even as major stock indices like the Nasdaq Composite and the S&P 500 exhibited slight declines, reflecting a somewhat uneven broader market environment. The Nasdaq dropped by 0.19%, and the S&P 500 receded by 0.20%, underscoring a day of mixed investor sentiment. Nonetheless, Revvity’s shares benefited from optimism fueled by early financial forecasts for both the fourth quarter and the 2025 fiscal year.
The company is preparing to publish its official financial results for these periods on February 2, 2026, but in advance, it disclosed preliminary expectations that notably exceeded market forecasts. For the fourth quarter, Revvity anticipates a roughly 6% increase in reported revenue, projecting around $772 million. This figure surpasses the analyst consensus estimate of $760.6 million and signals steady growth momentum. For the entire fiscal year 2025, the company forecasts revenues near $2.855 billion, representing an approximate 4% increase year-over-year and again outpacing the consensus of $2.84 billion.
Adding to this positive revenue indication, Revvity expects its adjusted earnings per share (EPS) for 2025 to surpass the higher end of its previously provided guidance range of $4.90 to $5.00. This suggests effective cost management and operational leverage supporting improved profitability.
Looking ahead to 2026, the company projects organic growth in the range of 2% to 3%. It also anticipates adjusted EPS growth in the high single digits. Management foresees the continuation of prevailing end-market trends, with a targeted adjusted operating margin around 28%, reinforcing expectations of robust operating efficiency.
Technically, Revvity’s stock currently demonstrates strong momentum. Trading levels are approximately 11.2% above the 20-day simple moving average and 17.5% above the 100-day simple moving average. Although shares have declined by over 10% over the past 12 months, they are now closer to their 52-week highs than lows, suggesting a potential recovery phase. Technical indicators provide a nuanced signal: the relative strength index (RSI) stands at 59.86, indicating neither overbought nor oversold conditions, while the moving average convergence divergence (MACD) is above its signal line, implying present bullish momentum. This mixed momentum profile warrants attention from traders for possible breakout movements.
Analysts maintain a generally positive stance on the stock, assigning it a Buy rating with an average price target of approximately $120.24. Recent updates from notable financial institutions include Barclays updating its rating to Overweight and raising its target to $115.00; Wells Fargo assigning an Equal-Weight rating with an increased target of $107.00; and Goldman Sachs initiating coverage with a Neutral rating and a target price of $105.00.
Valuation considerations point to a premium price-to-earnings multiple for Revvity’s stock. Still, the expected 8% earnings growth rate supports analyst consensus that the elevated valuation is warranted, implying a potential upside nearing 9% relative to current price targets.
A market positioning analysis by Benzinga Edge reveals some challenges amid strengths: the stock scores relatively weakly on momentum compared to the broader market, with a score of 18.91 out of 100. Its quality, assessed via balance sheet stability, is rated as neutral at 39.51, while value metrics are also weak, reflecting the premium at which the stock trades compared to its industry peers.
Among exchange-traded funds, the First Trust Indxx Medical Devices ETF holds a notable exposure to Revvity, accounting for approximately 2.18% of its portfolio.
In summary, Revvity's stock closed Tuesday with a gain of just over 6%, reaching $110.14, accompanied by encouraging preliminary financial projections. These factors, combined with technical and analyst support, create a cautiously optimistic outlook as the company approaches its formal earnings announcement.